Home
Screener
Insiders
Rankings
Sign in
Create account
Insiders
· Profile
Meyer Andrew Hollman
Chief Business Officer at Janux Therapeutics. Filing since 27 Sep 2024.
CIK 0001864159
Company
Date
Role
Action
Shares
Amount
Of holding
JANX
Janux Therapeutics, Inc.
2 Jan 2026
Chief Business Officer
Sold at will
1,879
$25.80K
2.2%
JANX
Janux Therapeutics, Inc.
1 Dec 2025
Chief Business Officer
Sold on a plan
3,333
$109.93K
3.8%
JANX
Janux Therapeutics, Inc.
14 Nov 2025
Chief Business Officer
Sold on a plan
3,333
$99.99K
3.8%
JANX
Janux Therapeutics, Inc.
28 Oct 2025
Chief Business Officer
Sold on a plan
16,665
$500.99K
16.9%
JANX
Janux Therapeutics, Inc.
1 May 2025
Chief Business Officer
Sold on a plan
3,333
$106.74K
3.9%
JANX
Janux Therapeutics, Inc.
21 Apr 2025
Chief Business Officer
Sold on a plan
3,334
$100.02K
3.9%
JANX
Janux Therapeutics, Inc.
3 Mar 2025
Chief Business Officer
Sold on a plan
3,334
$107.17K
3.9%
JANX
Janux Therapeutics, Inc.
3 Feb 2025
Chief Business Officer
Sold on a plan
3,334
$141.00K
3.9%
JANX
Janux Therapeutics, Inc.
2 Jan 2025
Chief Business Officer
Sold at will
13,334
$731.79K
14.0%
JANX
Janux Therapeutics, Inc.
27 Sep 2024
Chief Business Officer
Sold at will
50,000
$2.30M
42.5%
10 decisions on file.
